NR 293 Week 6 Assignment: RUA: Teaching Pamphlet – Nurtec (ODT)

Nurtec ODT (Rimegepant) Chamberlain College of Nursing NR 293 – Pharmacology Rimegepant (Nurtec ODT) is a medication that was first approved by the FDA on February 27, 2020, to be used as a treatment for acute mig ...

Nurtec ODT (Rimegepant) Chamberlain College of Nursing NR 293 – Pharmacology Rimegepant (Nurtec ODT) is a medication that was first approved by the FDA on February 27, 2020, to be used as a treatment for acute migraines (National Center for Biotechnology Information, 2020). Rimegepant is a calcitonin gene-related peptide receptor antagonist (CGRP), which is also referred to as gepants. Nurtec is the first CGRP to come in an orally disintegrating tablet but has drug interactions with CYP3A4 inhibitors, CYP3A inducers, and transporters. Rimegepant offers migraine relief to an expanded population when compared to triptans. Triptans constrict the blood vessels, which leaves a possibility for coronary artery construction as well. Since Nurtec does not have these properties, patients with hypertension or other heart-related problems are not contraindicated in this medication (Lipton, et al., 2020). Nurtec should be avoided in pregnant, breastfeeding patients or plan on becoming pregnant, the elderly, and children as there have not been enough clinical trials to show how it affects these individuals (Biohaven Pharmaceuticals, 2020). Nurtec is contraindicated in patients with liver impairment, end-stage renal disease, and hypersensitivity to any drug components (Biohaven Pharmaceuticals, 2020). This brochure should be used to give information to possible patients or patients who have recently been prescribed the medication. In addition, this brochure should also be shown to healthcare professionals or caregivers to understand how to administer the medication and properly inform/educate the client. This brochure is intended to inform the patient, caregiver, and healthcare professions about Nurtec. Throughout this brochure, patients will be able to identify indications of taking Nurtec, the side effects, possible toxicities, and give other nonpharmaceutical options to use in conjunction with or without Nurtec. This brochure will also help identify the classification of Nurtec, mechanism of action (how it works), and how to administer the medication properly. Although this brochure contains many informative aspects of Nurtec, it is crucial to understand that not all information is included, nor are all questions answered with given information. The best way to understand a new medication is to talk to the healthcare provider or your pharmacist. These individuals can answer why certain medications are prescribed to people, and some aren't. They can also help the patient understand more in-depth about the administration, what to expect, and the medication's effectiveness. References American Headache Society (2020). Rimegepant Approved by the FDA. Retrieved from https://americanheadachesociety.org/news/rimegepant-acute-migraine-treatment/ Biohaven Pharmaceuticals, Inc. (2020). Nurtec ODT for Healthcare Professionals. Retrieved from https://www.nurtec-hcp.com/ Lipton, R., Croop, R., Stock, E., Stock, D., Morris, B., Frost, M., Dubowchik, G., Conway, C., Coric, V., & Goadsby, P. (2019). Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine: NEJM. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa1811090 Gao, B., Yang, Y., Wang, Z., Sun, Y., Chen, Z., Zhu, Y., & Wang, Z. (2020). Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials. Frontiers in pharmacology, 10, 1577. https://doi.org/10.3389/fphar.2019.01577 National Center for Biotechnology Information (2020). PubChem Compound Summary for CID 51049968, Rimegepant. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Rimegepant.